A Phase I/II, Observer-Blind, Randomized, Active-Controlled Trial to Evaluate the Safety and Immunogenicity of a Two-Dose Series of GSK Biologicals' Candidate Influenza Vaccine GSK 1557484A Antigens With or Without Adjuvant

The purpose of this study is to evaluate the safety and immune response of two-doses of GSK Biologicals' candidate influenza vaccine GSK 1557484A with or without adjuvant in adults. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

本研究旨在评估两剂次葛兰素史克生物制品（GSK Biologicals）候选流感疫苗GSK 1557484A（含或不含佐剂（adjuvant））在成人人群中的安全性与免疫应答。为符合2007年9月出台的《美国食品药品监督管理局修订法案（FDA Amendment Act）》相关规定，本试验的方案公示内容已完成更新。